A 59 year old patient was referred to our department to detect disease activity related to clinical symptoms of tiredness, weight loss and an elevated serum serotonine, suspicious of a neuro-endocrine tumour. A 18F-fluoro-l-dihydroxyphenylalanine (FDOPA) PET/CT scan was performed, which showed focally increased uptake in the terminal ileum and in a mesenterial lymph node. Additionally, an area of intense uptake was observed intracranially. Histological analysis confirmed the presence of a WHO grade I meningioma. Few cases of FDOPA PET uptake in meningiomas have been published, underlining it is as a rare finding. Awareness of this potential finding is crucial to avoid misinterpretation as intracerebral metastasis.
A 59 year old patient was referred to our department to detect disease activity related to clinical symptoms of tiredness, weight loss and an elevated serum serotonine, suspicious of a neuro-endocrine tumour. A 18 F-fluoro-l-dihydroxy-phenylalanine (FDOPA) PET/CT scan was performed, which showed focally increased uptake in the terminal ileum and in a mesenterial lymph node (Fig. 1) . Additionally, an area of intense uptake was observed intracranially (Fig. 2a , left frontal region). The atypical location of the uptake suggested the presence of a mengioma (Fig. 2b) . Based on this PET finding, MRI was performed (2C), which showed an extra-axial mass with extensive contrast enhancement on T1 weighted imaging and a 'dural tail' , typical of meningioma. Additional findings on MRI were midline shift and edema. Histological analysis confirmed the presence of a WHO grade I meningioma. FDOPA PET has been used in the evaluation of brain tumours, among other PET techniques using amino acid tracers such as 11 C-methionine and tumour cells, which in turn use it for protein synthesis. In meningiomas, high LAT1 expression has been described (Zitron et al. 2013) . Consequently, increased uptake of FDOPA may be observed in these tumours. In addition, increased uptake of other amino acid PET tracers in meningiomas has been described, including a series of 10 meningiomas which showed increased uptake of -[ 11 C]methyl-L-tryptophan (AMT) (Zitron et al. 2013) . as well as of somatostatin radiolabelled analogs (Soto-Montenegro et al. 2014 ).
Conclusions
Few cases of FDOPA PET uptake in meningiomas have been published (Calabria et al. 2016 ), underlining it is as a rare finding. Awareness of this potential finding is crucial to avoid misinterpretation as intracerebral metastasis. 
